Unlock instant, AI-driven research and patent intelligence for your innovation.

Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof

A molecular and amino acid technology, applied in the field of tissue orientation and identification, which can solve the problems of difficult separation and display of monoclonal antibodies, high antibody immunogenicity, etc.

Inactive Publication Date: 2007-11-07
BIO TECH GENERAL CORP
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

One limitation is the difficulty of isolating suitable monoclonal antibodies that show selective binding
The second limitation is that a prerequisite for successful antibody isolation is the need for high antibody immunogenicity
A third limitation is that the final product contains non-human sequences that elicit an immune response to non-human material (e.g., human anti-mouse antibody-HAMA response)
In addition, there is an N-terminal propeptide that may be cleaved post-translationally

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
  • Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
  • Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0602] Embodiment 1: the preparation of platelet

[0603] A citrate dextrose (ACD) concentrate of platelets was obtained from a blood bank, platelets were isolated and washed once in a buffer containing ACD and saline at a ratio of 1:7. Platelets were centrifuged at 800 g for 10 min after each wash and resuspended in Tyrode's solution (2 mM MgCl 2 , 137mM NaCl, 2.68mM KCl, 3mM NaH 2 PO 4 , 0.1% glucose, 5 mM Hepes and 0.35% albumin, pH 7.35) and count the number of cells.

[0604] Preparation of platelet-rich plasma

[0605] Blood was collected into tubes containing 3.8% sodium citrate. Platelet-rich plasma was prepared by centrifugation at 250 xg for 10 minutes.

Embodiment 2

[0606] Example 2: Platelet Aggregation

[0607] For platelet aggregation studies, platelet-rich plasma (PRP) and washed platelets were stirred at 500 rpm at 37°C in a whole blood Lumiaggregometer (Chronolog, Havertown, PA). The difference in light transmission through the platelet suspension and the suspended medium was defined as 100% agglutination. The effect of YI on platelet aggregation was assessed by adding different concentrations of Y1 prior to the addition of the agonist, and the effect was recorded for 4 minutes.

Embodiment 3

[0608] Example 3: Treatment of platelets with endoproteases

[0609] 3.1 Cutting of platelets by Mocarhagin

[0610] For mocarhagin digestion, dissolve 10 mM CaCl in TS buffer (0.01M Tris, 0.15M NaCl, pH 7.4) with 12 µg / mL mocarhagin (final concentration) at 22°C. 8 Washed platelets were treated for 1 hour and digestion was terminated by adding EDTA to 0.01M.

[0611] 3.2 Cleavage of glycocalicin by cathepsin G

[0612] 10 in TS buffer containing 1 mM calcium chloride 8 Washed platelets were incubated with 1.8 μg / ml cathepsin G (final concentration) for 4 hours at 22°C, and digestion was terminated by adding PMSF to 1 mM.

[0613] 3.3 O-sialoglycoprotein cleavage of glycocalicin

[0614] At 37 ° C, containing 0.2% albumin and protease inhibitors (10 μ M leupeptin, 0.24 mM PMSF) 10 6 Platelets were incubated with 0.14 mg / ml endo-sialoglycoproteinase (final concentration) for 45 minutes, and digestion was terminated by adding sample buffer and boiling. The sample buffer ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

The present invention provides epitopes present on cancer cells and important in physiological phenomena such as cell rolling, metastasis, and inflammatio n. Therapeutic and diagnostic methods and compositions using antibodies capable of binding to the epitopes are provided. Methods and compositions according to the present invention can be used in diagnosis of and therapy for such diseases as cancer, including tumor growth and metastasis, leukemia, auto- immune disease, and inflammatory disease.

Description

field of invention [0001] The present invention relates to epitopes present on e.g. cancer cells, metastatic cells, leukemia cells and platelet cells, said epitopes being important in such different physiological phenomena as cell rolling, metastasis, inflammation, autologous Immune disorders such as idiopathic thrombocytopenic purpura (ITP), adhesions, thrombosis and / or restenosis, and agglutination. The present invention relates to therapeutic and diagnostic methods and compositions using antibodies raised against such epitopes. The invention also relates to the field of tissue targeting and identification by means of phage display technology of peptides and polypeptides that specifically bind to target cells. Such peptides and polypeptides are antibodies and antigen-binding fragments thereof, constructs thereof, antigen-binding fragments thereof or fragments of constructs thereof, or constructs of fragments. More particularly, the peptides and polypeptides may have antica...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K16/00C12N15/09A61K31/353A61K31/42A61K31/4709A61K31/522A61K31/5575A61K31/616A61K31/675A61K31/7072A61K31/711A61K31/727A61K31/728A61K35/12A61K38/00A61K39/00A61K39/395A61K51/00A61P7/02A61P9/10A61P29/00A61P35/00A61P35/02A61P35/04A61P37/02C07K2/00C07K14/47C07K16/18C07K16/30
CPCA61K38/00C07K2317/565C07K2317/622C07K14/472C07K16/3061A61P29/00A61P35/00A61P35/02A61P35/04A61P37/02A61P7/02A61P9/10C07K16/18
Inventor J·拉扎罗维茨Y·哈盖D·普拉克辛T·沃格尔A·尼姆罗德H·马-海姆E·桑通T·里希特B·阿米特L·库佩尔曼T·佩雷茨A·莱瓦农
Owner BIO TECH GENERAL CORP